2型糖尿病与氯吡格雷抵抗相关性的研究进展

doi:10.3969/j.issn.1671-7171.2018.01.027

摘要
图/表
参考文献
相关文章 (15)

[1] Parodi G,Marcucci R,Valenti R,et al.High residual platelet reactivity after clopidogrel loading and long-term cardiovascular events among patients with acute coronary syndromes undergoing PCI[J].JAMA,2011,306(11):1215-1223.
[2] AI-Azzam SI,Alzoubi KH,Khabour OF,et al.Factors that contribute to elopidogrel resistance in cardiovascular disease patients:environmental and genetic approach[J].Int J Clin Pharmacol Ther,2013,51(3):179-186.
[3] Ferreiro JL,Angiolillo DJ.Diabetes and antiplatelet therapy in acute coronary syndrome[J].Circulation,2011,123(7):798-813.
[4] Stone GW,Kedhi E ,Kereiakes DJ,et al.Differential clinical responses to everolimus-eluting and clitaxel-eluting coronary stents in patients with and without diabetes mellitus[J].Circulation,2011,124(8): 893-900.
[5] Angiolillo DJ,Suryadevara S.Aspirin and clopidogrel: efficacy and resistance in diabetes mellitus[J].Best Pract Res Clin Endocrinol Metab,2009,23(3):375-388.
[6] Angiolillo DJ,Fernandez-Ortiz A,Bernardo E,et al.Platelet function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment[J].Diabetes,2005,54(8): 2430-2435.
[7] Bonello L,Tantry US,Marcucci R,et al.Consensus and future directions oil the definition of high on-treatment platelet reactivity to adenosine diphosphate[J].J Am Coll Cardiol,2010,56(12):919-933.
[8] Ueno M,Ferreiro JL,Tomasello SD,et al.Functional profile of the platelet P2Y12 receptor signalling pathway in patients with type 2 diabetes mellitus and coronary artery disease[J].Thromb Haemost,2011,105: 730-732.
[9] Patti G,Proscia C,Di Sciascio G.Antiplatelet therapy in patients with diabetes mellitus and acute coronary syndrome[J].Circ J,2014,78(1):33-41.
[10] Mangiacapra F,Peace A,Barbato E,et al.Thresholds for platelet reactivity to predict clinical events after coronary intervention are different in patients with and without diabetes mellitus[J].Platelets,2014,25(5):348-356.
[11] Mathewkutty S,McGuire DK.Platelet perturbations in diabetes:implications for cardiovascular disease risk and treatment[J].Expert Rev Cardiovasc Ther,2009,7(5): 541-549.
[12] Golbidi S,Badran M,Laher I.Antioxidant and anti-inflammatory effects of exercise in diabetic patients[J].Exp Diabetes Res,2012,2012: 941868.
[13] Santilli F,Simeone P,Liani R,et al.Platelets and diabetes mellitus[J].Prostaglandins Other Lipid Mediat,2015,120:28-39.
[14] Suslova TE,Sitozhevskii AV,Ogurkova ON,et al.Platelet hemostasis in patients with metabolic syndrome and type 2 diabetes mellitus:cGMP-and NO-dependent mechanisms in the insulin-mediated platelet aggregation[J].Front Physiol,2015,5:501.
[15] Morel O,Kessler L,Ohlmann P,Atherosclerosis,et al.Diabetes and the platelet:toward new therapeutic paradigms for diabetic atherothrombosis[J].Atherosclerosis,2010,212(2):367-376.
[16] Yari F,Azadpour S,Shiri R.Platelet storage media change the expression characteristics of the platelet-derived microparticles[J].Indian J Hematol Blood Transfus,2014,30(3): 169-174.
[17] Wu ZH,Ji CL,Li H,et al.Membrane microparticles and diseases[J].Eur Rev Med Pharmacol Sci,2013,17(18):2420-2427.
[18] Santilli F,Vazzana N,Liani R,et al.Platelet activation in obesity and metabolic syndrome[J].Obes Rev,2012,13(1):27-42.
[19] Price MJ,Berger PB,Teirstein PS,et al.Standard-vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention:the GRAVITAS randomized trial[J].JAMA,2011,305(11):1097-1105.
[20] Roberts DI,Nawarskas JJ.Treatment options for patients with poor clopidogrel response[J].Cardiol Rev,2013,21(6):309-317.
[21] Saucedo JF.Antiplatelet therapy for patients with diabetes mellitus and acute coronary syndrome[J].Primary Care Diabetes,2012,6(3):167-177.
[22] Ha SJ,Kim SJ,Hwang SJ,et al.Effect of cilostazol addition or clopidogrel doubling on platelet function profiles in diabetic patients undergoing a percutaneous coronary intervention[J].Coron Artery Dis,2013,24(8):690-697.
[23] Jeong YH,Hwang JY.Adding cilostazol to dual antiplatelet therapy achieves greater platelet inhibition than high maintenance dose clopidogrel in patients with acute myocardial infarction: Results of the adjunctive cilostazol versus high maintenance dose clopidogrel in patients with AMI (ACCEL-AMI) study[J].Circ Cardiovasc Interv,2010,3(1):17-26.
[24] Park KW,Kang SH.Adjunctive cilostazol versus double-dose clopidogrel after drug-eluting stent implantation:The HOST-ASSURE randomized trial (Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis-Safety &Effectiveness of Drug-Eluting Stents &Anti-platelet Regimen) [J].JACC Cardiovasc Interv,2013,6(9):932-942.
[25] Wiviott SD,Desai N,Murphy SA,et al.Efficacy and safety of intensive antiplatelet therapy with prasugrel from TRITON-TIMI 38 in a core clinical cohort defined by worldwide regulatory agencies[J].Am J Cardiol,2011,108(7):905-911.
[26] Mega JL,Close SL,Wiviott SD,et al.Cytochrome P450 genetic polymorphisms and the response to prasugrel:relationship to pharmacokinetic,pharmacodynamics,and clinical outcomes[J].Circulation,2009,119(19):2553-2560.
[27] Aradi D,Tornyos A,Pinter T,et al.Optimizing P2Y12 receptor inhibition in patients with acute coronary syndrome on the basis of platelet function testing:impact of prasugrel and high-dose clopidogrel[J].J Am Coll Cardiol,2014,63 (11):1061-1070.
[28] Wallentin L,James S,Storey RF,et al.Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes:a genetic substudy of the PLATO trial[J].Lancet,2010,376(9749):1320-1328.
[29] Alexopoulos D,Xanthopoulou I,Mavronasiou E,et al.Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with diabetes[J].Diabetes Care,2013,36(8):2211-2216.
[30] Ferreiro JL,Ueno M,Tello-Montoliu A,et al.Effects of cangrelor in coronary artery disease patients with and without diabetes mellitus: An in vitro pharmacodynamic investigation[J].J Thromb Thrombolysis,2013,35(2): 155-164.
[31] Steg PG,Bhatt DL,Hamm CW,et al.Effect of cangrelor on periprocedural outcomes in percutaneous coronary interventions:a pooled analysis of patient-level data[J].Lancet,2013,382(9909):1981-1992.